Introduction
Bioanalytical proteomics workflows originally consisted of the qualitative profiling of two or more samples/groups using gel-based separation techniques with some type of optical read-out [1, 2] . The benefits of mass spectrometry were readily recognised with the development of in-gel digestion and peptide extraction techniques in combination with peptide mass fingerprint MALDI time-of-flight [3] and nanoelectrospray tandem mass spectrometry [4] making protein identification more routine and main stream. The following advances included the use of one and two-dimensional nanoscale LC chromatography, originally developed by the chromatographic community but embraced and brought forward by the proteomics community because of increased method sensitivity, which afforded the analysis of more complex samples in an automated fashion. Meanwhile, continued high-resolution mass spectrometer developments, such as modes of acquisition, resolution, analyzer types and combinations, speed and sensitivity, lead to the identification of more proteins and putative disease markers at increasingly faster identification rates. The more recent developments include the incorporation of orthogonal separation techniques within instruments designs, as for example, ionic gas phase based ion-mobility [5, 6] .
Quantitation in discovery LC-MS based proteomics experiments is typically conducted by either labelled or label-free methods. Labels can be incorporated metabolically or by using chemical techniques [7, 8] . In both instances, a known or predictable peptide mass shift is introduced, affording the differential quantitation of peptides and their parent proteins. The read-out can be either at the precursor, including techniques such as ICAT, SILAC, dimethyl-labelling [9] [10] [11] , or at the product ion level, of which iTRAQ and TMT labelling are representatives [12, 13] . The former methods limit the experimental design in terms of the number of samples that can be compared, but arguably provide the best precision, whereas the latter methods provide a higher degree of multiplexing but at the cost of reduced dynamic quantitation range. Label-free methods have gained great popularity over the last decade with ion abundance based methods believed to provide the best accuracy and precision [14] [15] [16] . Appealing benefits of these methods are the increased dynamic range and the freedom in experimental design compared to quantitative labelled LC-MS methods. An additional benefit is that the amount of the identified proteins can be estimated without the use of stable isotope labelled standards [17] . Attention has to be given however to experimental variation as this is carried through and affects the total observed error.
Targeted LC-MS based assays are increasingly applied in the post-discovery proteomics area with emphasis on validation, the first of many phases in translational analyses, or in studies that are aimed at gaining the understanding of biological systems, drug development and treatment. Context is driving current proteomics experiments, thereby also driving the development of LC-MS acquisition methods that can provide both qualitative and quantitative information in a single experiment. With the increased availability of spectral libraries and public discovery results repositories [18, 19] , the identification of disease related or pathway associated proteins is not seen, or at least strongly reduced, as a prerequisite for larger scale, confirmatory type studies. Moreover, targeted, multiplexed assays are believed to be a viable alternative for antibody based assays because of improved specificity. Both tandem quadrupole and high-resolution mass spectrometers are applied for these types of studies [20] [21] [22] [23] . Multiple/selected reaction monitoring (MRM/SRM) based assays are especially believed to have the potential to afford protein quantitation with the reproducibility and throughput required in order to improve biomarker acceptance. These types of experiments are however technologically challenged since they require analyzing a large number of samples with high-throughput, but also require high sensitivity, high resolution, large dynamic range and excellent selectivity at the same time. Here, tandem quadrupole and high-resolution mass spectrometers are systematically compared to demonstrate and contrast the application of these analyzer types and how they could be operated for targeted protein quantitation experiments. In addition, two different types of LC interfaces have been evaluated with regard to their contribution to throughput/robustness vs. sensitivity. A small cohort of heart failure disease patient blood samples was analyzed. Heart failure (HF) poses a significant burden on healthcare systems around the world. The causes of HF are disparate and can involve interplay between several biological systems [24] . An examination of the expression of thirteen proteins that populate biological pathways intertwined with HF will test the feasibility and potential use of LC-MRM-MS for translational analysis.
Experimental Conditions
Blood sample collection and plasma extraction Human blood samples were collected from a cohort of twenty healthy donors, twenty heart failure with preserved ejection fraction (HFPEF) patients, and twenty heart failure with reduced ejection fraction (HFREF) patients, following informed consent. All HFPEF patients had an ejection fraction of ≥50% and HFREF patients had an ejection fraction ≤40%. A volume of 20 mL of blood was collected in a Sterilin tube containing 330 μL of Trasylol (= 3000 Kallikrein Inhibitor Units) and 80 μL of 1 M EDTA per 20 mL of blood. The blood was mixed before centrifugation at 15 000 g at 4 °C for 30 min. The plasma layer was separated from the buffy layer and red blood cells, and stored at -80 °C.
Protein digestion protocols
Twenty microliters of undepleted human EDTA test sample plasma (Sigma-Aldrich, St. Louis, MO) for the comparative configuration part of the study was diluted with 80 μL of 50 mM ammonium bicarbonate solution and denatured in the presence of 10 μL of 1% RapiGest (Waters Corporation, Milford, MA) detergent solution at 80 °C for 45 min. The plasma proteins were reduced in the presence of 5 μL of 100 mM dithiothreitol at 60 °C for 30 min. and alkylated in the dark in the presence of 6 μL of 200 mM iodoacetamide at ambient temperature for 30 min. Proteolytic digestion was initiated by adding 40 μL of 1 µg/μL sequencing grade, modified trypsin (Promega, Madison, MI) and incubated overnight at 37 °C. Breakdown of the acid-labile detergent was achieved in the presence of 1% TFA at 37 °C for 45 min. The peptide solutions were centrifuged at 13,000 rpm for 10 min, and the supernatants collected.
Patient and donor plasma samples were digested as previously described with minor modifications [25] . RapiGest solution was then added to the samples to give a 0.1% final concentration and incubated at 80 °C for 45 min. The samples were then reduced with 100 mM aqueous DTT solution added to give a final concentration of 5 mM prior to incubation at 60 °C for 30 min. A 200 mM IAA solution was added to the samples to give a final concentration of 10 mM before incubation in the dark at room temperature for 30 min. A trypsin solution of 1 μg/μL was added to the sample in a 1:50 w/w ratio and incubated at 37 °C overnight. Digestion was concluded, and RapiGest cleaved, with the addition of neat formic acid to the sample to give a final concentration of 0.5%. The plasma samples were centrifuged at 13,000 rpm for 10 min to remove insoluble material, and the supernatants collected.
LC configurations
1D nanoscale LC separation of tryptic peptides was performed with a Acquity M-class system (Waters Corporation), equipped with a Symmetry C18 5 µm, 2 cm x 180 µm precolumn and an HSS T3 C18 1.8 µm, 25 cm x 75 µm analytical RP column (Waters Corporation). The samples were transferred with aqueous 0.1% (v/v) formic acid to the precolumn at a flow rate of 5 µL/min for 3 min. Mobile phase A was water containing 0.1% (v/v) formic acid, whilst mobile phase B was acetonitrile containing 0.1% (v/v) formic acid. After desalting and preconcentration, the peptides were eluted from the precolumn to the analytical column and separated with a gradient of 3-40% mobile phase B over 90 min at a flow rate of 300 nL/min, followed by a 2 min column rinse with 85% of mobile phase B. The columns were re-equilibrated at initial conditions for 20 min. The analytical column temperature was maintained at 35 ºC.
Additional, higher throughput experiments were performed with 150 µm × 100 mm ionKey/MS micro-fluidics packed with BEH C18 1.7 μm [26] . Gradient conditions were from 3-40% B gradient over 45 min at a flow rate of 1 µL/min, followed by a 6 min column wash with 85% of mobile phase B. The columns were re-equilibrated at initial conditions for 9 min. The analytical column temperature was maintained at ambient temperature. Samples were injected/loaded directly on-column or using a precolumn configuration. In this instance, the precolumn was 5 cm x 300 µm id, packed with 5 µm Symmetry C18 and samples loaded with a flow rate of 15 µL/min for 1 min. Faster reversed phase gradient separation, both nanoscale LC and micro-fluidics based, were explored but not considered for detailed analysis as (isobaric) interferences or detection issues were readily observed, as exemplified in Supplementary Figure 1 , hampering more detailed comparative configuration analysis.
MS configurations
Multiple Reaction Monitoring (MRM) analysis was performed using two tandem quadrupole mass spectrometers, Xevo TQ-S and Xevo-TQ-S micro, and two hybrid quadrupole orthogonal acceleration time-of-flight platforms, Xevo G2-XS Q-ToF and Synapt G2-Si (Waters Corporation, Wilmslow, United Kingdom). The Synapt G2-Si instrument is equipped with a travelling wave ion, tri-wave ion guide, which comprises two stacked ring collision induced dissociation (CID) regions, separated by a travelling wave guide that can be used for ion mobility separation. This configuration is described in detail elsewhere [6, 27] . All experiments were performed in positive electrospray ionisation (ESI) mode. The ion source block temperatures and capillary voltages were kept constant for all instruments and set to 70 ºC and 3.2 kV. Micro-fluidics interfaced experiments were typically conducted with a slightly increased capillary voltage of 3.6 kV. The N2 cone gas flow and nanoflow gas pressure were 35 L/h and 0.2 bar, respectively, whereas the Ar collision gas flow equalled 2 mL/min. The quadrupole and time-of-flight analyzers were externally calibrated with NaCsI mixtures from m/z 50 to 1990.
A number of instrument and analyzer specific parameters, as well as the acquisition types, used in this study are presented in Table 1 . Endogenous and stable isotope labelled (SIL) peptides were targeted by at least three transitions with a minimum of 10 data points over a chromatographic peak. Tandem quadrupole dwell and interscan delay times were automatically calculated by the operating software based on a minimum number of data points specified at half height across a chromatographic peak. Collision energies were set at fixed values for the tandem quadrupole instruments and ramped for the time-of-flight instrument. In addition, for the time-of-flight based MRM acquisitions, integration and interscan delay times were manually set. Collision energies were ramped and initially calculated using the following regression equation: 0.034 times m/z + 3.314 eV, and further optimized by CID fragmentation evaluation obtained by repeat injections of SIL peptides in the absence of matrix. The MRM transitions for both instrument types are listed in Supplementary Table 1.
Experimental designs
Fifteen stable isotope labelled (SIL) peptides (PepScan, Lelystad, Netherlands), representing putative blood-based cardiovascular disease protein biomarkers spanning over five orders of dynamic concentration range [28] , were initially spiked as a dilution series from 6.25 amol to 12.5 fmol on-column, in tryptic digested EDTA human plasma. The SIL peptides and associated proteins of interest are shown in Table 2 , including normal plasma protein and molar peptide concentration values [29] . In total, considering all LC-MS configurations and column/interface formats, 108 LC-MS experiments were conducted. Extended dynamic range experiments were conducted with one of the SIL peptides at spike levels ranging from 7.5 amol to 1.5 pmol, in tryptic digested human plasma as well.
The healthy donor, HFPEF and HFREF plasma samples were spiked post-digestion at four individual different levels of 0.25, 0.5, 2 and 10 fmol each with the same fifteen SIL peptides, analyzed separately, providing multiple, user selectable quantitation levels and surrogate technical replicates, mounting to a total of 240 LC-MS experiments (~ 10 days of measurement time).
Sulfadimethoxine base sensitivity analysis
Base sensitivity analysis were conducted with Xevo TQ-S micro and Xevo G2-XS QToF platforms, both operated in positive ion mode ESI and interfaced to an Acquity Hclass system (Waters Corporation), and sulfadimethoxine (Sigma-Adrich) as the test analyte. The source temperature was maintained at 150 ºC, the desolvation temperature at 550 ºC, the desolvation gas flow at 1000 L/h, and the capillary voltage set at 4 kV. Mobile phase A was aqueous 0.1% (v/v) formic acid/0.05% (v/v) ammonia solution, and mobile phase B acetonitrile containing 0.1% (v/v) formic acid. The column was 2.1 x 50 mm packed with BEH 1.7 µm stationary phase (Waters Corporation), operated at 0.8 mL/min, and maintained at 40 °C.
Informatics
Tandem quadrupole and high resolution Q-ToF LC-MS peptide MRM data were quantified with either TargetLynx (Waters Corporation) or Skyline [30] , and analyzed and visualized with Spotfire v6.0.0 (TIBCO software, Boston, MA). All statistical analyses were conducted with SIMCA (v14, MKS Umetrics AB, Umeå, Sweden) or IBM SPSS statistics v22 (IBM Corporation, Armonk, NY).
Orthogonal partial least squares-discriminant analyses (OPLS-DA) were performed on the candidate peptides as a ratio to their labelled standard and all data Pareto scaled. Sample runs that deviated significantly from the Hotelling's T 2 95% confidence interval were excluded and the model refitted. Peptides considered as contributing to the supervised separation of groupings were identified by consultation of the accompanying S-plot. OPLS-DA models were produced for control subjects vs. those with heart failure, and for heart failure with reduced ejection fracture vs. preserved ejection fraction.
Pair-wise comparisons for identified peptides of interest were performed by the Mann Whitney U test for independent samples. Logistic regressions were performed to calculate the probabilities of heart failure prediction for each individual peptide of interest, and as a combination of all these peptides. Receiver operator characteristic curves were produced using these probabilities and the areas under the curve were calculated. All tests with a two-tailed p value of <0.05 were deemed as statistically significant.
Results and discussion
Biomarker discovery and validation are the first steps in understanding disease and finding surrogate markers for drug development. Validation is challenged since it requires the analysis of a large number of samples with high-throughput, but also with high sensitivity, reproducibility, robustness, accuracy and precision over a large dynamic range. Targeted LC-MS based assays have been shown previously to afford protein quantitation with the reproducibility and throughput required in order to improve biomarker acceptance [31] . MRM based assays on tandem quadrupole instruments have been the primary technology used, but more recently higher mass resolution system and those incorporating and hybridising ion mobility with high resolution mass spectrometry have been described.
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) designed a series of interrelated studies to assess the reproducibility and quantitative characteristics of tandem/triple quadrupole based MRM assays [32] [33] [34] [35] , as well as developing reference materials, software tools, and guidelines for data sharing. Tandem and triple quadrupole mass spectrometers were applied in these studies since they are the quantitation 'gold standard', providing a high speed multiplexing capability compared to other analyzer types, a large linear dynamic range of quantitation, and have good sensitivity, signal-tonoise and specificity. Despite this, tandem quadrupole based MRM has been challenged and criticized from both a biological and technical perspective, and mass spectrometry based alternatives, using high-resolution mass analyzers, explored [23, [36] [37] [38] [39] . Notwithstanding these challenges, tandem/triple quadrupole mass spectrometers have been successfully applied for the quantitative analysis of proteins. As an example, Carr et al. [40] reported on the efficient quantitation of low-abundance plasma proteins, representing an 800-plex MRM based LC-MS assay, run in a single analysis, comprising 2400 transitions with retention time scheduling to monitor 400 unlabeled and heavy labelled peptide pairs.
Analytical performance and ion transmission
One of the evaluated tandem quadrupole MS platforms in this study was also used in the CPTAC studies [32] [33] [34] [35] and numerous other biomarker studies including the previously mentioned highly multiplexed study [40] . This platform will be used as the base for the comparative experiment, with emphasis on sensitivity, throughput/speed, selectivity, precision and accuracy for the quantitation of peptides and proteins. From a theoretical perspective, a number of parameters need to be considered when comparing tandem mass spectrometry geometries. The first mass analyzer of all platforms comprises a quadrupole ion guide. The transmission of these devices typically ranges from 50 to 80% at 0.7 Da FWHM resolution [41] . Within a tandem quadrupole configuration, the overall transmission would equal the product of the transmission of the individual analysers. In a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer, the transmission across a narrow m/z range can approach 100% if the pusher is synchronized with the output from the collision cell [42] . An approach has previously been described that can maximise the duty cycle of the orthogonal acceleration time-of-flight (oa-ToF) to close to 100% across the m/z range using the synchronization of the ion mobility separation stage with the pusher of the oa-ToF [43] . Thus, dependent upon the configuration, an oa-ToF analyzer is close to the transmission of a quadrupole ion guide operated at unit resolution. However, compounding duty cycle are interscan delay times and the number of measured transitions. Quadrupole interscan delay times can be as small as 1 ms, not noticeably affecting transmission, whereas currently oa-ToF interscan delay times are around 5-15 ms, resulting in lower duty cycle at higher acquisition rates.
In terms of absolute sensitivity, in practice, tandem/triple quadrupole and (hybrid) oa-ToF performances can be found to be comparable. For example, for a single transition for the analysis of sulfadimethoxine the lower limits of detection (LLOD) and quantitation (LLOQ) for a tandem quadrupole (Xevo TQ-S micro) and an oa-ToF (Xevo G2-XS QTof) platform were both found to be equal to 5 and 10 µg on-column. Shown in Supplementary Figure 2 are the MRM chromatograms for the transition(s) of sulfadimethoxine on both MS platforms, illustrating that the base performance/sensitivity and ion transmission for the analysis of a single compound in isolation are almost identical, under the same experimental conditions. The next paragraphs will demonstrate how the evaluated geometries compare for the multi-analyte MRM analysis of endogenous and SIL peptides spiked in undepleted digested plasma matrix and that the single analyte observations also hold for multi-analyte experiments.
Transition selection and optimization
The collision cells used in all evaluated MS geometries utilize similar low energy CID fragmentation characteristics. Shown in Figure 1 , as an example, are the full scan MS/MS spectra for one of the SIL peptides, namely FPEVDVLTK-13 C6 15 N2. The top (A) pane illustrates a tandem/triple quadrupole MS/MS spectrum, the middle (B) pane an oa-ToF equivalent, and the bottom (C) pane an enhanced duty cycle (EDC) oa-ToF full scan spectrum. As can be noted, the profiles of the tandem quadrupole and oa-ToF MS/MS spectra share great similarity, suggesting that transitions can be derived from oa-ToF based discovery experiments and translated to tandem MS geometry independent MRM transitions [44] . Also shown is that the EDC oa-ToF MS/MS spectrum, centering at m/z 682.4, is promoting over a relative wide m/z range of a few hundred Th wide across the product ion range of interest, thereby somewhat skewing the relative abundances of the product ions and their associated ratios, but significantly increasing sensitivity. Maximum duty cycle is retained in this way of operating EDC oa-ToF MRM acquisitions since only a single m/z value is synchronised. The spectra shown in panels B and C of Fifteen peptides, representing thirteen proteins were selected from the study by Domanski et al. [28] , covering more than five orders of plasma protein concentration dynamic range. Selection rules taken into consideration were concentration, amino acid composition and sequence length. The fifteen SIL peptide equivalents listed in Table 1 were pooled at equimolar levels and analyzed by both data independent analysis (DIA; MS E -style) [45, 46] and precursor isolated MS/MS experiments in the absence of matrix to examine fragmentation behaviour and product ion distribution. Only y" fragment ions were considered and the CID collision energies and ramps optimized for maximum product ion intensity distribution and circumventing over or under fragmentation using the collision energy regression rules described in the section Experimental Conditions as the initial collision energy values. A minimum of three transitions/product ions per peptide were selected, one peptide excluded. The selected precursor and product ion target masses, constituting the MRM transitions, are overviewed in Supplementary Table  1 . The endogenous target masses were determined by calculation. EDC m/z selection was based upon the relative product ion intensity (abundance) of a fragment m/z value within the region of interest (precursor m/z < EDC m/z < ymax m/z). In practice this is close to the center of the m/z range, obtained from either an experimental DIA or MS/MS product ion spectrum.
Technical and experimental variation
Several sources contribute to assay variation, including technical, experimental, and biological variation (sampling, sample preparation (solid phase extraction, digestion, pipetting, LC-MS, etc.). The variation, precision and confidence level are significant factors in determining that a given study has appropriate power and are critical when designing a translational biomarker study. The imprecision, bias, and total allowable error, calculated from data on within-subject and between-subject biologic variation for clinical assays, including plasma proteins, have been populated in a database [47, 48] , and recently updated [47] . Accessing the biological protein plasma concentration variation of a population and the individual component and summed technical experimental variation by means of LC-MS is beyond the scope of this study; however, variation should be considered when developing and specifying quality requirements in relation to the size of the cohort to be studied. Table 3 summarizes the biological variation of a number of the proteins of which the peptides have been examined in this study as determined by accepted clinical assays. The variation is greatly protein dependent, which will determine the consideration of LC-MS as an alternative and viable technology, for example where immunoassays fail [49] , as well as cohort/sample size [31] . As an example of technical variation LC-MS tandem quadrupole MRM precision was assessed to provide an appreciation of the application of LC-MS in translational studies. More extensive experimental variation study results are published in more detail elsewhere [50] , including digestion [51] [52] [53] , which is widely quoted and seen as a major source of variation. Three SIL peptides were spiked in fifty independent, undepleted, tryptic digested plasma samples and the absolute and relative transition abundances measured. The results shown in the top (A) pane of Figure 2 illustrate the raw summed abundances are sample dependent and different trends can be observed for the three peptides of interest. The latter can be explained by the fact that the (biological) background will vary per unit (chromatographic) time as the matrices are different for every sample but would mimic the effects observed in a larger cohort study. The left bottom (B) pane summarizes the result in box-and-whisker format with uncorrected CV values ranging from about 10 to 30%. The middle bottom pane (C) illustrates the consistency of the relative abundances of the transitions (intensity of the most abundant transition/intensity sum of all transitions). This characterizes the magnitude of internal standard correction, in terms of reducing CV values from raw to relative values, and reduces the CV values by a factor of two to five. Normally, this would be achieved by contrasting the abundances of the endogenous peptides of interest with those on its SIL counterpart and assessed with informatics tools such as m-prophet [54] or AuDIT [55] . The bottom right (D) pane results illustrate retention time reproducibility numbers, which was on average close to 0.5% CV.
Throughput and speed of analysis
The fastest gradient separations possible were employed without introducing isobaric interferences for the fifteen SIL peptides monitored for both LC platforms. As the microfluidics interface is operated at a higher flow-rate, and the number of connectors and connection lines reduced compared to a typical nanoscale LC set-up, system volumes are more quickly 'swiped', providing reduced gradient delivery delays and faster column conditioning. Moreover, extra-column volumes will be less critical at higher flow-rates. Typical nanoscale LC and micro-fluidics tandem quadrupole MRM chromatograms for 125 amol SIL peptides injected on-column are shown in Supplementary Figure 3 , illustrating an average increase in speed of analysis of 1.9 for 150 µm inner diameter (id) microfluidics vs. 75 µm id nanoscale LC tryptic peptide separations at nearly identical linear mobile phase velocities. The complete experimental injection-to-injection cycle times were 1 and 2 h for the micro-fluidics and nanoscale LC based separations, providing a 2-fold increase in throughput for the micro-fluidics experiments. Average peak widths at half-height W0.5 were 0.07 and 0.12 min, respectively, mounting to similar peak capacity approximations of 320 and 375, assuming that the chromatographic separations spaces were 45 and 90 min. Retention time reproducibility (data not shown) was in both cases better than 1%.
Quantitative comparison of platforms and column geometries
The linear response and the peak-to-peak signal-to-noise (S/N) at a given concentration level were determined and the lower limit of detection estimated for a dilution series of the fifteen SIL peptides, representing thirteen proteins, spiked into undepleted, tryptic digested plasma. The injected plasma digest on-column amount, assuming a normal total protein concentration of 70 g/L, equalled 140 ng. S/N values were determined at 12.5 amol injected on-column for the 75 µm id nanoscale LC based experiments and at the 125 amol level for the 150 µm id micro-fluidics LC-MS separations, respectively. The MS response and assay sensitivities were initially tested from 6.25 amol to 12.5 fmol for the nanoscale LC based experiments and from 62.5 amol to 12.5 fmol for the micro-fluidics separations, with the tested dynamic range extended for a subset of configurations, including additional technical LC-MS replicates, as described below.
The results are summarized in Table 4 and Supplementary Table 2 . Within the tested range, exceeding three orders of concentration dynamic range, all mass spectrometers demonstrated 1/x weighted linear behaviour with r 2 regression correlation coefficient values of 0.9909 or greater for all SIL peptides. Similarly, the S/N values measured at the 12.5 amol and 125 amol spike level were found to be comparable for the majority of the SIL peptides measured with all LC-MS configurations, ranging from 2 to 30 for the 75 µm id nanoscale LC setup, and 2 to 100 for the 150 µm id micro-fluidics configuration, respectively. The median and average lower limit of detection (LLOD) values, across all MS platforms equalled 5 and 8 amol for the 75 µm id nanoscale LC experiments, and 20 and 39 amol for the 150 id micro-fluidics LC-MS. The experiment also afforded calculation of the concentration of some of the endogenous peptides that were within the measured dynamic range. The results shown in Table 5 overview the determined concentrations of the endogenous peptides (proteins) for the 75 µm id nanoscale LC based experiments and Supplementary Table 3 for the 150 µm id micro-fluidics LC-MS separations, respectively. The concentration and coefficient of variation (CV) were calculated for each individual SIL spike-level, representing a multi-level single point average and error estimate. The average CV values, across all MS platforms as well, for the nanoscale LC and micro-fluidics experiments were found to be equal to 8.6 ± 3.5% and 10.3 ± 4.7%, respectively. The MRM data of the LC platform/configuration comparative part of the study are provided in 'Supplementary Information -LC-MS Configuration Comparison'.
Extended dynamic range experiments
Despite quite similar and impressive levels of analytical performance, the best overall/combined performance in terms of CV precision and throughput, see previous sections, was obtained with the 150 µm id micro-fluidics interface in combination with one of the tandem quadrupole mass spectrometers. The dynamic range of the assay was extended and the detection of the lower abundant target peptides improved by using a trap-column based LC configuration of which the details are provided in the Experimental section. This column configuration allows for the loading of five-fold more protein plasma digest without affecting the chromatographic performance of the system (data not shown) and afforded the detection of fourteen of the fifteen target peptides/proteins in undepleted plasma. Linear response was observed for LGPLVEQGR-
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15 N4 from 15 amol to 1.5 pmol injected on-column in the presence of matrix, representing five orders of magnitude of linear LC-MS response, as illustrated in Supplementary Figure 4 , with a median %CV value, for the individual SIL standard levels, of 5.5%, and a r 2 regression correlation coefficient of 0.9842.
Mobility enabled MRM methods
IM enabled oa-ToF MRM acquisition modes can provide either increased selectivity or sensitivity. These modes could be useful for lower level peptides that challenge assay specificity and are briefly described with example results presented. With the mobility enabled oa-ToF platform, the collision cell/mobility separation region comprises three stacked ring ion guide devices placed in series (tri-wave). The first region can be used to either trap ions or conduct CID fragmentation. Within the second region, the ions, either precursor or product ions, dependent on the use of the trap region, undergo mobility separation. In the third region, the ions are either transferred to the oa-ToF analyzer or CID fragmented. The device has been described in detail elsewhere [26, 56, 57] , as well as alternative uses of stacked ring ion guides, including electron transfer dissociation [58] and top-down type studies [59] . The two cases described here are graphically summarized in Figure 3 . The top (A) pane illustrates a case where ion mobility separation is achieved in the second region and CID conducted in the third region, aiming at achieving additional assay selectivity. The bottom (B) pane demonstrates ion mobility separation at the product ion level which is aimed at increasing sensitivity across the complete m/z fragment ion range by optimizing the duty cycle of the instrument. In short, product ions are trapped within the first region of the tri-wave device and gated into the high-pressure ion mobility region where they are separated according to their gas phase mobility, which is predominantly determined by mass, charge, size, and shape. As a result, fragment ions of the same mobility exit the cell as a series of compact packets. Hence, by synchronizing the pusher pulse that accelerates the fragment ions into the oa-ToF mass analyzer with the arrival of product ions into the pusher region, fragment ions are sequentially injected into the ToF analyzer with greatly enhanced duty cycle (~ 85%) across the mass scale [43] .
The benefit of the latter case is illustrated in Figure 4 , showing typical sub 100 amol on-column results obtained with oa-ToF MRM data collected in normal MRM mode using EDC in the top (A) pane and with product ion IM separation in the bottom (B) pane. Data were normalized to the endogenous level to account for any experimental LC-MS variation and collected in so-called isotope stripping mode, whereby only isotopic information is stored for a pre-defined set of product ions, reducing file size significantly without losing quantitative information. As can be seen, the mobility enabled method provided better sensitivity. The effect of EDC can be noted as illustrated by the relative high intensity of the high mass vs. the low mass product ions, which was aimed at sacrificing the low m/z product ion region nearly completely by promoting the oa-ToF duty cycle for the more specific high m/z product ions. An example of the former mentioned IM enabled oa-ToF MRM method, where additional precursor and product ion separation can be achieved of co-isolated peptides that differ in ion mobility characteristic or CCS value, prior to CID in the transfer region of the tri-wave mobility/collision cell, is shown in Figure 5 . The application of these highly selective oaToF modes of acquisition for the quantitation of peptides and proteins will be published in a separate communication.
Application results
Heart failure represents a heterogeneous clinical population for which biomarkers are sparse. The aetiology of the disease also means that the phenotypic changes are likely to be multifactorial. As a proof of principle and test of overall sensitivity to classify this heterogeneous disease, twenty healthy controls, twenty patients with HFPEF and twenty heart failure patients with HFREF were analyzed. For this particular application, the micro-fluidics interface, equipped with a pre-column, was used in combination with one of the tandem quadrupole mass spectrometers, as it provided the best combination of throughput, loadability, sensitivity, precision and linearity. The micro-fluidics gradient conditions were adjusted to the previously described experiments, namely from 2 to 30% B in 45 min at 35 °C, to increase chromatographic resolution. Multivariate analysis of proteins showed that patient samples could be classified using OPLS-DA, using the data and results obtained from one of the SIL spike level (10 fmol) experiments, as illustrated by the scores distribution/summary in Figure 6 . Partial separation of healthy controls and HF (combined HFPEF and HFREF) can be observed. Fit (R 2 ) and prediction (Q 2 ) values of 0.52 and 0.38 were obtained, respectively, for the developed model. The three proteins contributing mostly to the separation, as identified by analyzing the loadings distributions, covariance vs. correlation, were Apolipoprotein A-1 (APOA), Plasma protease C1 inhibitor (SERPING1) and C-reactive protein (CRP). Univariate analysis of these three proteins showed significant changes in levels between the groups, as summarized in Figure 7A -C. Good discriminant power was obtained by combining these protein surrogate peptides, with an area under the receiver operating characteristic curve of 0.937 obtained as illustrated in Figure 7D . Previous work demonstrated that ApoA1 is potentially protective in HF, so the lower observed levels in the HF group would be consistent [60] . CRP is well known to increase with heart failure [61] , and plasma protease C1 inhibitor may well be indicative of remodelling, which is a clear pathophysiological mechanism in heart failure. Distinct separation between all three groups, namely control, HFPEF and HFREF, was not obtained with the selected subset of peptides, however, a partial separation model could be developed for HFREF and HFPEF, see Supplementary Figure 5 . These results suggest that a classification model can be achieved with a multi-analyte LC-MRM-MS assay, using tandem quadrupole mass spectrometry combined with micro-fluidics, and a subset of three proteins from the thirteen proteins examined. Improvements to the model would necessitate a larger cohort of samples or the use of other peptides/proteins, which was outside the scope of this study. However, the strength of the model and the biological processes identified as contributing to the model indicate that this approach may yield successful opportunities for biomarker research. The MRM data of the biological part of the study are provided in 'Supplementary Information -Application Results'.
Conclusions
LC-MRM-MS has been adopted and widely applied in translational biomarker studies due to the inherent speed of developing a multiplexed assay that can be deployed with relatively high sensitivity and throughput. In this study, building upon previous studies, the effect of both the LC scale and the choice of MS platform has been investigated. In biomarker discovery, many performance studies have been conducted using extensively high performance LC-MS systems. However, the technical and performance challenges in biomarker translation studies are different and require a robust and reliable platform, with good quantitative precision that can analyse much larger cohorts of samples. The results presented show that with regard to the LC component, despite nanoscale LC being the predominant separation technology in quantitative protein biomarker studies, it was found that a larger 150 µm inner diameter scale micro-fluidic based system has the required sensitivity and quantitative performance, combined with throughput characteristics required for quantitative translational studies.
In the case of the MS platform, the use of higher resolution systems can have significant benefits in the targeted analysis of biomarkers in biological matrices. The elevated resolution can often be translated in increased specificity and therefore a more reliable measure of a peptide and hence proteins abundance. In this study, looking at a range of peptides in undepleted human plasma, the sensitivity was found to be very comparable between the modern tandem quadrupole and the quadrupole time-of-flight systems, but the combination of a high sensitivity tandem quadrupole with a microfluidic inlet provided the best coefficient of variation, throughput and sensitivity/signalto-noise. It may be surprising, in some regards, that the elevated resolution of the second mass analyser of the time-of-flight systems does not translate to into improved quantitative performance, but in this study the peptides, even at levels close to their lower limit of quantitation provided a linear response with all MS platforms.
The preferred instrument configuration was used for the analysis of the selected peptides, and hence proteins, originating from heart failure disease patients, and compared to matched control samples. This preliminary study was designed to test the overall sensitivity and to classify this heterogeneous disease, resulting in separation of the two disease groups from the control group and partial separation of the two disease phenotypes. The multiplex assay will be further tested on a larger cohort of heart failure patients to test the classification. This study has shown that the applied LC-MS platform demonstrates suitable throughput and sensitivity to accommodate analysis of much larger cohorts that are typical in cardiovascular biomarker discovery (>1000 patient samples). Moreover, what is particularly attractive about this configuration is that the step from initial discovery to verification of initial candidates can be rapidly executed using a targeted MS approach rather than an alternative such as immunoassay or western blot which are potentially more expensive, less specific and consume more sample than the methods described here. Thus, the transition from discovery to validation is greatly accelerated. Additionally, it is plausible that further candidates could be integrated with relative ease, providing future flexibility and with little detriment to throughput.
LC-MS technology continues to mature and the current technology has the required analytical performance to make large-scale biomarker translation studies a reality. This combined with the ability to build highly flexible, multiplexed assays will ensure that the technology will have an impact in the detection and monitoring of complex heterogeneous diseases. LGPLVEQG CVI = within-subject (intra-individual) coefficient of variation; CVG = between-subject (inter-individual) biological variation Table 4 . Quantitative response, S/N and estimated LLOD of fifteen SIL peptides spiked into undepleted, tryptic digested human serum using tandem quadruple and oa-ToF mass spectrometry in combination with nanoscale LC (see section Experimental for details). The levels tested ranges from 6.25 amol to 1.25 fmol on-column. 
